Company intelligence / Profile preview

Curis Law

Lexington, Massachusetts, United Statescuris.com ↗

Ownership: Private
Employees: ~33
Development stage: Other

Overview

Curis's lead candidate emavusertib is an orally available small molecule IRAK4 inhibitor in Phase 1/2 trials for hematologic malignancies including AML, hrMDS, and PCNSL. The company also has a marketed product, Erivedge® (vismodegib), licensed to Genentech/Roche for advanced basal cell carcinoma. Additional pipeline assets target immune checkpoints and epigenetic regulators.

Therapeutic areas: OncologyHematology
Modalities: Small moleculeProtein
Industry: Biotech

Partnerships

Aurigene Discovery Technologies Limited [collaboration/licensing partner for emavusertib and other pipeline assets; exclusive licensee of key IP]Genentech/Roche [licensee/commercialization partner for Erivedge®]National Cancer Institute [research collaboration]

Beyond the preview

Go deeper on Curis Law.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curis Law.

Explore the full profile